[
    [
        {
            "time": "2018-01-02",
            "original_text": "基金4季报控盘股TOP20:恒华科技、健帆生物超33%",
            "features": {
                "keywords": [
                    "基金",
                    "4季报",
                    "控盘股",
                    "TOP20",
                    "恒华科技",
                    "健帆生物"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "基金4季报控盘股TOP20:恒华科技、健帆生物超33%",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]